Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
Aripiprazole (1) ·
Banisteriopsis caapi (1) ·
Black Drink (1) ·
Bromazolam (1) ·
Brugmansia (1) ·
Bupropion / Naltrexone (1) ·
Butalbital / Acetaminophen / Caffeine (1) ·
Chocolate (1) ·
Ciprofloxacin (1) ·
Gabapentin (1) ·
Guarana (1) ·
Hyoscyamus niger (1) ·
Kola (1) ·
Mandragora officinarum (1) ·
Mescal Bean (1) ·
Nutmeg (1) ·
Olanzapine (1) ·
Phentermine (1) ·
Promethazine (hydrochloride) (1) ·
Psilocybin (1) ·
Tea (1) ·
Yerba mate (1)
brand:
''Brugmansia'' spp., Angel's trumpet, ''borrachero'', ''toé'' (1) ·
''Camellia sinensis'' (formerly ''Thea sinensis'') (1) ·
''Cola nitida'', ''Cola acuminata'' (1) ·
''Ilex paraguariensis'' (1) ·
''Ilex vomitoria'' (1) ·
''Myristica fragrans''. Mace (the fruit aril) (1) ·
''Paullinia cupana'' (1) ·
''Sophora secundiflora''. Texas mountain laurel, frijolillo (1) ·
''Theobroma cacao'' (1) ·
(none, never marketed) (1) ·
Abilify (oral), Abilify Maintena (monthly IM LAI), Aristada (aripiprazole lauroxil IM LAI), Abilify Asimtufii (bi-monthly IM LAI), Abilify MyCite (digital ingestion sensor) (1) ·
Adipex-P, Lomaira (low-dose); with topiramate as Qsymia (1) ·
Cipro, Cipro XR, Ciloxan (ophthalmic) (1) ·
COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1) ·
Contrave (US), Mysimba (EU) (1) ·
Fioricet, Esgic; with codeine as Fioricet with Codeine (Schedule III) (1) ·
Henbane, black henbane (1) ·
Mandrake (1) ·
Neurontin (IR), Gralise (ER), Horizant (gabapentin enacarbil ER) (1) ·
Phenergan, Promethegan (suppositories) (1) ·
The ayahuasca vine, ''yagé'', ''caapi'', ''mariri'' (1) ·
Zyprexa (oral, IM acute), Zyprexa Zydis (ODT), Zyprexa Relprevv (LAI), Lybalvi (with samidorphan) (1)
classes:
mechanism:
None (8) ·
Active alkaloid is cytisine, a nicotinic acetylcholine receptor agonist. NOT a classical 5-HT2A psychedelic. (1) ·
Active oils are myristicin, elemicin, and safrole, phenethylamine precursors that may be aminated in vivo to MMDA, TMA, and MDA respectively (Shulgin's 'essential amphetamines' hypothesis). (1) ·
Caffeine (1.5–2%) + theobromine + kolanin (a glycoside). (1) ·
Caffeine (highest of the ''Ilex'' genus) plus saponins that produce ritual vomiting at high doses. (1) ·
Caffeine (sometimes called 'mateine' historically, though chemically identical), theobromine, theophylline, plus polyphenols. (1) ·
Caffeine + theophylline + L-theanine. L-theanine (an amino acid unique to tea) modulates glutamate and produces an 'alpha-wave' calming overlay on caffeine's stimulation, hence tea's reputation as a 'cleaner' stimulant than coffee. (1) ·
Contains the β-carboline alkaloids harmine, harmaline, and tetrahydroharmine, reversible monoamine oxidase inhibitors (RIMAs) that allow oral DMT to reach the brain. (1) ·
Highest natural caffeine content of any plant (2–7% by dry weight, ~2–4× coffee). Caffeine is bound to tannins, producing a slower release than pure coffee caffeine. (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Primary alkaloid is theobromine (3,7-dimethylxanthine), with minor caffeine. Also contains phenethylamine, anandamide (an endogenous cannabinoid), tryptophan (serotonin precursor), and flavanols. The combined effect is mild stimulation + mood elevation. (1) ·
Prodrug to [[Psilocin|psilocin]] (4-hydroxy-N,N-dimethyltryptamine), a partial agonist at the [[Receptor:5-HT2A|5-HT2A]] serotonin receptor; the action that defines the classical-psychedelic mechanism (1) ·
Tropane alkaloids: hyoscyamine, scopolamine, atropine, apoatropine. (1) ·
Tropane alkaloids: hyoscyamine, scopolamine, in higher seed concentrations than belladonna or datura. (1) ·
Tropane alkaloids: scopolamine (dominant), hyoscyamine, atropine. Competitive antagonism at muscarinic acetylcholine receptors. (1)
uses:
(investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000006-QINU`"' (3) ·
'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' (3) ·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"' (1) ·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1) ·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (1) ·
'"`UNIQ--vote-00000065-QINU`"' (1) ·
'"`UNIQ--vote-000000AD-QINU`"', '"`UNIQ--vote-000000AE-QINU`"' (1) ·
'"`UNIQ--vote-000003A0-QINU`"', '"`UNIQ--vote-000003A1-QINU`"' (1) ·
'"`UNIQ--vote-0000069B-QINU`"', '"`UNIQ--vote-0000069C-QINU`"' (1) ·
'"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"' (1) ·
'"`UNIQ--vote-0000081E-QINU`"' (1) ·
'"`UNIQ--vote-00000932-QINU`"', '"`UNIQ--vote-00000933-QINU`"', '"`UNIQ--vote-00000934-QINU`"', '"`UNIQ--vote-00000935-QINU`"', '"`UNIQ--vote-00000936-QINU`"', '"`UNIQ--vote-00000937-QINU`"' (1) ·
'"`UNIQ--vote-0000129E-QINU`"' (1) ·
'"`UNIQ--vote-00001567-QINU`"' (1) ·
'"`UNIQ--vote-0000159D-QINU`"', '"`UNIQ--vote-0000159E-QINU`"' (1)
starting dose:
None (10) ·
0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use (1) ·
1-2 capsules (50 mg butalbital / 325 mg acetaminophen / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) ·
15-37.5 mg PO once daily before breakfast or 1-2 hours after; Lomaira 8 mg TID (1) ·
300 mg PO at bedtime night 1, 300 mg BID day 2, 300 mg TID day 3; titrate to clinical effect, commonly 1800-3600 mg/day divided TID (1) ·
500-750 mg PO BID; 400 mg IV q8-12h (1) ·
Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated''' (1) ·
Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
One cup (~40–60 mg caffeine; about half of brewed coffee) (1) ·
Schizophrenia / acute mania: 5-10 mg PO once daily, target 10-15 mg/day. Acute agitation IM: 10 mg, may repeat in 2 hours. Relprevv LAI: 150-300 mg every 4 weeks after oral overlap (1) ·
Schizophrenia/bipolar mania: 10-15 mg PO once daily, target 15-30 mg. MDD adjunct: 2-5 mg/day, target 5-15 mg. Pediatric autism irritability: 2 mg, titrate to 5-15 mg. Maintena LAI: 400 mg IM every 4 weeks after oral overlap (1) ·
Week 1: 1 tablet (8/90 mg) PO morning; week 2: 1 tablet AM + 1 PM; week 3: 2 AM + 1 PM; week 4 onward: 2 AM + 2 PM (32 mg naltrexone / 360 mg bupropion/d) (1)
preparations:
15, 30, 37.5 mg capsules/tablets; 8 mg Lomaira (1) ·
250, 500, 750 mg IR tablets; 500, 1000 mg ER tablets (XR); 250, 500 mg/5 mL oral suspension; 200, 400 mg IV; 0.3% ophthalmic solution and ointment; 0.2% otic (1) ·
50/325/40 mg capsules and tablets; oral solution (1) ·
8 mg naltrexone / 90 mg bupropion ER tablets (titration-pack design) (1) ·
Bark/woody stem decocted with a DMT-source plant (''Psychotria viridis'', ''Diplopterys cabrerana'') to make ayahuasca (1) ·
Bright red seeds, traditionally ingested or smoked. Highly toxic, narrow margin between active and lethal (1) ·
Capsules 100, 300, 400 mg; tablets 600, 800 mg; oral solution 250 mg/5 mL; Gralise ER tablets 300, 600 mg (once-daily); Horizant ER tablets 300, 600 mg (gabapentin enacarbil, an inactive parent compound metabolized to gabapentin in vivo) (1) ·
Dried leaves and twigs, infused in a gourd (''mate'') and drunk through a metal straw (''bombilla'') (1) ·
Dried leaves, infused. Six major processings: white, green, yellow, oolong, black, pu-erh (1) ·
Fermented and roasted seeds, ground. Mexican tradition: drunk with chili, cornmeal, achiote. European tradition: with sugar and milk (1) ·
Flowers or leaves infused or smoked. Highly variable potency; narrow toxic margin (1) ·
Fresh nuts chewed; also dried and powdered (1) ·
Ground dried seed (nutmeg) or fruit aril (mace); occasionally infused (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) ·
Leaves and seeds, traditionally smoked or infused. Possibly the original Pythia oracle plant (1) ·
Roasted seeds ground to powder, mixed with water; commercial syrups and energy drinks (1) ·
Root, traditionally carved into ''mannikens'' or infused into wine (1) ·
Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1) ·
Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL (1) ·
Tablets 2, 5, 10, 15, 20, 30 mg; ODT 10, 15 mg; oral solution 1 mg/mL; acute IM injection 9.75 mg/1.3 mL; Maintena LAI 300, 400 mg monthly; Aristada LAI 441, 662, 882, 1064 mg (4-8 week dosing); Asimtufii bi-monthly (1) ·
Tablets 2.5, 5, 7.5, 10, 15, 20 mg; ODT (Zydis) 5, 10, 15, 20 mg; acute IM injection 10 mg/vial; Relprevv LAI 210, 300, 405 mg vials (1) ·
Toasted leaves and twigs decocted to a near-black concentrate (1)
fda max:
None (12) ·
100 mg/day (adult) (1) ·
20 mg/day (oral) (1) ·
30 mg/day (adult schizophrenia); 15 mg/day (MDD adjunct) (1) ·
32 mg naltrexone / 360 mg bupropion per day (1) ·
3600 mg/day; off-label doses higher are common but bioavailability saturates well below this (1) ·
37.5 mg/d (1) ·
6 capsules/d (300 mg butalbital, 1950 mg acetaminophen, 240 mg caffeine) (1) ·
N/A (never approved) (1) ·
Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1) ·
~1500 mg/d (oral); 1200 mg/d (IV) (1)
routes: (Click arrow to add another value)
onset:
None (10) ·
1-2 weeks for neuropathic pain and anxiolytic effect; anticonvulsant effect at therapeutic plasma level (1) ·
15–30 min (1) ·
20 minutes (oral); 5 minutes (IV) (1) ·
20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1) ·
30-60 minutes (1) ·
Appetite suppression within hours; weight loss over weeks-months (1) ·
Hours (1) ·
Modest appetite suppression within weeks; weight loss over months (1) ·
Neuroleptic effect emerges over days to weeks; activation symptoms (akathisia, insomnia) often within days (1) ·
Sedation from first dose; neuroleptic effect emerges over days to weeks (1) ·
Slow, 2–6 h (1) ·
~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (10) ·
12 hours (BID dosing required) (1) ·
12–24 h or longer (1) ·
24 hours (oral); 2-4 weeks (LAI) (1) ·
24 hours (oral); 4-8 weeks (LAI) (1) ·
3–4 h (1) ·
4-6 hours (3) ·
6–10 h subjective; full pharmacologic effect considerably longer. (1) ·
8-12 hours (1) ·
TID dosing for IR; once-daily for ER formulations (1) ·
~12-14 hours (1)
halflife:
None (11) ·
12-15 hours'"`UNIQ--ref-00000022-QINU`"' (1) ·
21-54 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
4 hours'"`UNIQ--ref-00000938-QINU`"' (1) ·
5-7 hours'"`UNIQ--ref-00000029-QINU`"' (1) ·
Butalbital ~35 hours (long; cumulative effects with frequent use); acetaminophen 1-3 hours; caffeine 3-7 hours'"`UNIQ--ref-0000159F-QINU`"' (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
Naltrexone ~4 hours (6β-naltrexol metabolite ~13 hours); bupropion ~21 hours'"`UNIQ--ref-00001568-QINU`"' (1) ·
Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption (1) ·
~25 hours'"`UNIQ--ref-0000129F-QINU`"' (1) ·
~5 h (caffeine) (1) ·
~75 hours (long, accumulates over weeks)'"`UNIQ--ref-00000023-QINU`"' (1)
bioavailability:
None (12) ·
'''Saturable''' via the LAT-1 amino-acid transporter, producing nonlinear pharmacokinetics: ~60% at 300 mg single dose, falling to ~35% at 1200 mg single dose'"`UNIQ--ref-0000002A-QINU`"' (1) ·
Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"' (1) ·
High (oral)'"`UNIQ--ref-000012A0-QINU`"' (1) ·
Naltrexone ~5% (oral, extensive first-pass to 6β-naltrexol); bupropion ER ~87%'"`UNIQ--ref-00001569-QINU`"' (1) ·
Not formally characterized in humans. (1) ·
Oral bioavailability of psilocin from administered psilocybin approximately 50% (1) ·
~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"' (1) ·
~60% (oral); ~100% (IM)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"' (1) ·
~87% (oral)'"`UNIQ--ref-00000024-QINU`"' (1)
pregnancy:
None (12) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern); use only when benefit clearly outweighs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Contraindicated in pregnancy (FDA label).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally avoided; barbiturate exposure in late pregnancy can produce neonatal withdrawal and respiratory depression.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; some signal for cardiac malformations and developmental delay but confounded by maternal disease and polytherapy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not studied in human pregnancy; no approved clinical use in any population (1) ·
Older agent with substantial use experience, including in hyperemesis gravidarum; broadly reassuring observational data'"`UNIQ--ref-00000024-QINU`"' (1) ·
Signal for gestational diabetes and metabolic syndrome with maternal exposure; the metabolic load can be substantial during pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal: (Click arrow to add another value)
Showing below up to 22 results in range #1 to #22.